期刊文献+

沙利度胺治疗系统性红斑狼疮皮疹的疗效研究

下载PDF
导出
摘要 目的探讨沙利度胺治疗系统性红斑狼疮皮疹的疗效、治疗的最适剂量、维持治疗时间及不良反应。方法收集我院32例系统性红斑皮疹患者,予不同剂量沙利度胺治疗,评估其临床疗效及不良反应。治疗前后采用配对t检验。结果沙利度胺50~75 mg/d治疗时,可见较好的疗效及较少的不良反应,维持治疗3~4周完全患者缓解率明显升高。SLE患者的其他指标如SLE疾病活动指数、红细胞沉降率及C反应蛋白水平、SLE疾病活动指数均显著下降(P〈0.05)。患者最常见的不良反应为困倦、头晕和便秘,无其他严重的不良反应。结论沙利度胺治疗系统性红斑皮疹患者安全,适宜推荐剂量50~75 mg/d,维持治疗时间为3~4周。
出处 《中国医药指南》 2016年第22期101-102,共2页 Guide of China Medicine
  • 相关文献

参考文献5

  • 1Karim MY,Ruiz-Irastorza G,Khamashta MA,et al.Update on therapy-thalidomide in the treatment of lupus[J].Lupus,2001,10(3):188-192.
  • 2Housman TS,Jorizzo JL,Mc Carty MA,et al.Low-dose thalidom ide t he r apy for r ef r a c t or y cut a ne ou s le sion s of lupu s erythematosus[J].Arch Dermatol,2003,139(1):50-54.
  • 3Coelho A,Souto MI,Cardoso CR,et al.Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus:a 65series of Brazilian patients[J].Lupus,2005,14(6):434-439.
  • 4Walchner M,Meurer M,Plewig G,et al.Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus[J].Int J Dermatol,2000,39(5):383-388.
  • 5王世颖,王丹丹,陈海凤,邹耀红,潘解萍,李晶,王向党,任天丽,张育,陈志伟,孙凌云.沙利度胺治疗狼疮皮疹的多中心研究[J].中华风湿病学杂志,2013,17(6):392-395. 被引量:1

二级参考文献33

  • 1Sheskin J. Thalidomide in the treatment of lepra reactions. ClinPharmacol Ther, 1965, 6: 303-306.
  • 2Doherty SD, Hsu S. A case series of 48 patients treated withthalidomide. J Drugs Dermatol, 2008, 7: 769-773.
  • 3Guti6rrez-Rodriguez 0. Starusta-Bacal P, Guti6rrez-Montes O.Treatment of rheumatoid arthritis: the thalidomide experience. JRheumatol, 1989, 16: 158-163.
  • 4Hamuryudan V,Mat C, Saip S,et al. Thalidomide in the treat-ment of the mucocutaneous lesions of Behcet's syndrome: a ran-domised, double-blind. placebo controlled trial. Ann InternMed, 1998, 128: 443-459.
  • 5Van Rhee F, Dhodapkar M, Shaughnessy JJ, et al. Firstthalidomide clinical trial in multiple myeloma: a decade. Blood,2008, 112:1035-1038.
  • 6Reyes-Teran G, Sierra-Madero JG, Martinez DCV, et al. Effectsof thalidomide on HIV-associated wasting syndrome: a ran-domised ,double-blind, placebo-controlled clinical trial. AIDS,1996, 10: 1501-1507.
  • 7Vogelsang GB, Farmer ER,Hess AD, et al. Thalidomide for thetreatment of chronic graft-versus-host disease. N Engl J Med,1992,326: 1055-1058.
  • 8Kuhn A,Ochsendorf F, Bonsmann G. Treatment of cutaneouslupus erythematosus. Lupus, 2010,19: 1125-1136.
  • 9Kuhn A, Ruland V,Bonsmann G. Cutaneous lupus erythem-atosus :update of therapeutic options part H . J Am Acad Der-matol ,2011, 65: el95-e213.
  • 10Kaur I,Dogra S,Narang T, et al. Comparative efficacy ofthalidomide and prednisolone in the treatment of moderate tosevere erythema nodosum leprosum: a randomized study. Aus-tralas J Dermatol, 2009, 50: 181-185.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部